Cellectis (CLLS) Share-based Compensation Growth (5y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123.23% |
| Dec 31, 2025 | 22.95% |
| Sep 30, 2025 | -243.15% |
| Jun 30, 2025 | -21.93% |
| Mar 31, 2025 | -27.21% |
| Dec 31, 2024 | 217.44% |
| Sep 30, 2024 | -135.84% |
| Jun 30, 2024 | -162.88% |
| Mar 31, 2024 | -29.50% |
| Dec 31, 2023 | -10.52% |
| Sep 30, 2023 | 218.14% |
| Jun 30, 2023 | -184.01% |
| Mar 31, 2023 | -33.02% |
| Dec 31, 2022 | -49.23% |
| Sep 30, 2022 | -4.96% |
| Jun 30, 2022 | -17.47% |
| Mar 31, 2022 | -29.83% |
| Dec 31, 2021 | -32.78% |
| Sep 30, 2021 | -16.35% |
| Jun 30, 2021 | -24.49% |
| Mar 31, 2021 | -71.07% |
| Dec 31, 2020 | -17.09% |
| Sep 30, 2020 | -20.32% |
| Jun 30, 2020 | -10.13% |
| Mar 31, 2020 | 38.15% |